Edition:
India

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

32.84USD
1:30am IST
Change (% chg)

$0.22 (+0.67%)
Prev Close
$32.62
Open
$33.07
Day's High
$33.11
Day's Low
$32.47
Volume
197,451
Avg. Vol
370,502
52-wk High
$38.52
52-wk Low
$12.59

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics Announces Proposed Public Offering Of Common Stock
Thursday, 12 Sep 2019 

Sept 11 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.FATE THERAPEUTICS INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.FATE THERAPEUTICS INC - ALL SHARES OF COMMON STOCK TO BE SOLD IN OFFERING WILL BE OFFERED BY CO.FATE THERAPEUTICS - INTENDS TO USE PROCEEDS FROM OFFERING TO FUND CLINICAL TRIALS AND NONCLINICAL STUDIES, MANUFACTURE OF CLINICAL PRODUCT CANDIDATES.FATE THERAPEUTICS - TO USE PROCEEDS FROM OFFERING FOR EXPANSION OF CGMP COMPLIANT MANUFACTURING OPERATIONS, CONDUCT OF PRECLINICAL RESEARCH & DEVELOPMENT.  Full Article

Fate Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
Wednesday, 6 Mar 2019 

March 5 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $1.7 MILLION VERSUS $1.0 MILLION.Q4 REVENUE ESTIMATE $2.9 MILLION -- REFINITIV IBES DATA.QTRLY NET LOSS PER COMMON SHARE $0.25.Q4 EARNINGS PER SHARE VIEW $-0.24 -- REFINITIV IBES DATA.  Full Article

Fate Therapeutics Says FDA Clears IND Application For Cell Therapy Derived From An Engineered Pluripotent Stem Cell
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR WORLD’S FIRST CELL THERAPY DERIVED FROM AN ENGINEERED PLURIPOTENT STEM CELL.FATE THERAPEUTICS INC - FT516 OFF--SHELF NK CELL CANCER IMMUNOTHERAPY CLEARED FOR CLINICAL INVESTIGATION BY FDA.FATE THERAPEUTICS INC - FDA HAS ALLOWED ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR FT516.FATE THERAPEUTICS INC - COMPANY INTENDS TO INITIATE CLINICAL TESTING OF FT516 IN PATIENTS WITH CERTAIN RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES.  Full Article

Fate Therapeutics Says NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies, Solid Tumors
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES ENCOURAGING DOSE-ESCALATION CLINICAL DATA OF FATE-NK100 AND PROVIDES REGULATORY UPDATE ON LANDMARK IND APPLICATION FOR FT500.NK100 SHOWS CLINICAL BENEFIT IN TREATING ADVANCED HEMATOLOGIC MALIGNANCIES AND SOLID TUMORS.SUBMITTED DATA TO FDA DEMONSTRATING FT500 MASTER IPSC BANK IS FREE OF ADVENTITIOUS AGENTS.  Full Article

Fate Therapeutics Prices Public Offering Of 9.26 Mln Common Shares At $13.50/Share
Friday, 21 Sep 2018 

Sept 20 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.26 MILLION COMMON SHARES PRICED AT $13.50PER SHARE.  Full Article

Fate Therapeutics Announces Proposed Public Offering Of Common Stock
Friday, 21 Sep 2018 

Sept 20 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.FATE THERAPEUTICS - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL TRIALS AND NONCLINICAL STUDIES, AMONG OTHERS.  Full Article

BRIEF-Fate Therapeutics Announces FDA Clearance Of Ind Application For First-Ever Ipsc-Derived Car T-Cell Therapy

* FATE THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR FIRST-EVER IPSC-DERIVED CAR T-CELL THERAPY